<DOC>
	<DOCNO>NCT02366975</DOCNO>
	<brief_summary>There many evidence literature show metabolic syndrome ( MetS ) associate BPH / LUTS . There also numerous evidence hypogonadism associate condition , thus one probable pathogenetic factor underlie association MetS &amp; BPH / LUTS . Preliminary evidence observational clinical study show treatment testosterone replacement hypogonadal patient MetS reduce symptom low urinary tract symptom ( LUTS ) associate BPH . Preclinical study perform investigator research group show experimental model metabolic syndrome occurrence mark inflammation tissue remodel prostate gland , prevent treatment testosterone replacement ( Vignozzi et al. , 2012 ) . There therefore need clinical trial demonstrate effect treatment testosterone replacement reduce inflammation prostate effectiveness improve symptom related inflammation patient prostatic BPH associate metabolic syndrome testosterone deficiency . The aims present study evaluate effectiveness testosterone replacement therapy compare placebo reduce sign symptom inflammation prostate LUTS symptom hypogonadal patient metabolic syndrome BPH candidate radical prostatectomy simple . For purpose clinical ( assessment specific symptom prostatitis assess questionnaire National Institutes Health Chronic Prostatitis Symptom Index , NIH-CPSI assessment symptom LUTS questionnaires International Prostate Symptom Score , IPSS ) , ultrasound ( transrectal ultrasound evaluation marker prostatic inflammation : macrocalcifications , inhomogeneity etc . ) , biochemical ( evaluation inflammatory cytokine semen ) , urodynamic histology ( histomorphometric immunohistochemical analysis sample prostate derive patient enrol study treat testosterone ) score perform . Along symptoms clinical sign prostate inflammation LUTS , effect testosterone therapy placebo penile erection also evaluate .</brief_summary>
	<brief_title>TRT BPH Hypoganadal MetS Patients . Florence-PROTEST</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male subject age ≥ 18 year wait list simple prostatectomy BPH Diagnosis metabolic syndrome ( AHA / NHLBI ) define presence three follow parameter : visceral obesity ( waist circumference &gt; = 102 cm ) , fast glucose ( &gt; = 100 mg / dL ) history diabetes mellitus treatment antidiabetic drug , high triglyceride ( &gt; = 150 mg / dL ) treatment , high level blood pressure ( BP &gt; = 130/85 mm Hg ) drug treatment reduce level HDL cholesterol ( &lt; = 40 mg / dL ) treatment . Diagnosis prostatic inflammation define score great 15 NIHCPSI questionnaire Capacity give consent study participation , adequately inform aim , benefit , risk , time motion study Participation another clinical trial ; Previous diagnosis , presence suspect malignancy prostate breast cancer ; PSA values10ng/mL Values hematocrit ≥ 52 % Use 5alphareductase inhibitor drug previous three month ; Presence serious organic disease mental diagnose specialist psychiatrist ( eg major depression medication ) suspect basis medical history / physical examination patient Presence condition may affect compliance study ; Presence severe allergy hypersensitivity study drug ( active ingredient excipients formulation ) ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BPH/LUTS</keyword>
	<keyword>TRT</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>